皮肤科治疗市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按应用、药物类别、地区、竞争细分

2022 年全球皮肤科治疗市场价值为 184.5 亿美元，预计在预测期内将出现显着增长，预计到 2028 年复合年增长率将达到 8.33%。该市场致力于皮肤科治疗领域，包括影响皮肤、头髮、指甲和黏膜的疾病和病症的诊断、治疗和管理。皮肤科作为一门专门的医学学科，解决各种与皮肤相关的问题，从痤疮和湿疹等常见病症到皮肤癌和自体免疫疾病等复杂疾病。皮肤病治疗的核心目标是提供全面的护理，包括医疗、外科和美容干预，所有这些都旨在保持或增强皮肤健康和美观。

在皮肤病治疗领域，各种各样的治疗方式开始发挥作用，包括从外用乳膏和软膏到口服药物和生物疗法的药物干预措施。这些治疗策略策略性地用于缓解症状、减轻发炎、对抗感染和调节潜在的疾病过程。

许多引人注目的因素促成了市场的成长轨迹。首先，皮肤病的发生率不断上升，包括但不限于痤疮、牛皮癣、湿疹、皮肤癌和真菌感染，是一个重要的驱动因素。皮肤相关疾病的上升趋势是由多种因素推动的，包括人口老化和环境因素对皮肤健康的持久影响。因此，对解决这些病症的有效治疗方案的需求不断增加。

市场概况
预测期	2024-2028
2022 年市场规模	184.5亿美元
2028 年市场规模	297.4亿美元
2023-2028 年复合年增长率	8.33%
成长最快的细分市场	牛皮癣
最大的市场	北美洲

此外，人们对护肤意识的不断增强和对美学问题的日益关注正在重塑这一格局。这种意识的转变很大程度上是由社交媒体的普遍影响、流行的美容趋势以及对更年轻外表的普遍渴望所推动的。这转化为对皮肤科产品和程序的需求增加，包括抗衰老治疗和药妆品。

主要市场驱动因素

意识和美学意识的提高

与老化相关的美学问题，例如细纹、皱纹和老年斑，推动了对抗老化皮肤科产品和治疗的需求。这包括使用外用乳膏、肉毒桿菌等注射剂和雷射治疗。许多人寻求真皮填充剂来增加脸部体积并实现更年轻的外观。这些治疗通常属于皮肤病治疗领域。化学换肤可用于嫩肤、改善皮肤纹理以及解决色素沉着不规则等美学问题。人们对疤痕（无论是手术、痤疮还是受伤）的美观担忧导致了对疤痕管理产品和治疗的需求。对更明亮、更均匀肤色的渴望推动了解决色素沉着过度和黄褐斑等问题的皮肤科产品市场。痤疮是一种常见的皮肤病，可能会导緻美观问题，尤其是当它导致疤痕时。皮肤病治疗药物，包括处方药和非处方药，在痤疮管理和减少疤痕方面受到追捧。

人们越来越意识到紫外线辐射的破坏性影响和防晒的重要性，导致人们更多地使用防晒霜和皮肤癌预防疗法等皮肤科产品。社群媒体、美容影响者和名人代言的影响使人们更加关注自己的外表和护肤程序。这促进了对各种皮肤科产品的需求。消费者可以获得比以往更多的信息，使他们能够自我了解护肤和皮肤科产品的好处。这种教育通常会提高产品的采用率。皮肤病治疗变得更加个人化，可以满足个人的护肤需求。通常由皮肤科医生推荐的客製化护肤方案已经很受欢迎。由于减少了停机时间和获得自然的效果，人们对雷射治疗和微晶磨皮等微创美容手术的偏好有所增加。名人公开讨论他们的护肤程序以及对特定产品或疗法的认可可以显着影响消费者的选择并刺激需求。美丽理想的全球化，透明和健康的皮肤被认为具有普遍吸引力，导致了全球对皮肤科产品和治疗的需求。这项因素将有助于全球皮肤病治疗市场的发展。

生物技术的进步

生物技术促进了针对各种皮肤状况的创新和有针对性的治疗方法的开发。生物技术已经能够创造出治疗牛皮癣、异位性皮肤炎和化脓性汗腺炎等皮肤病的生物药物。这些药物通常是单株抗体，针对免疫系统或发炎途径中的特定分子，提供更精确、更有效的治疗，且副作用更少。生物技术的进步促进了皮肤科的个人化医疗。基因测试和生物标记分析使皮肤科医生能够根据个人的基因组成和疾病特征量身定制治疗方案，从而提高治疗效果和安全性。生物技术促进了先进药物传递系统的发展，例如奈米颗粒和脂质体，它们增强了治疗剂对皮肤的渗透。这项创新提高了局部皮肤病治疗的有效性。生物技术催生了皮肤病学的再生医学方法。干细胞疗法和组织工程有望修復受损皮肤并治疗慢性伤口和疤痕等疾病。包括基因定序和分子诊断在内的生物技术工具可以更准确、更早地诊断皮肤病。及时、准确的诊断推动了对适当治疗方法的需求。生物技术导致了用于皮肤病治疗的生物相容性和生物可吸收材料的开发，例如用于美容和重建目的的真皮填充剂和缝合线。

生物技术提高了实验室培养皮肤细胞和组织的能力。这有助于研究、药物测试和新型皮肤病疗法的开发。正在进行的基因治疗研究有望透过纠正或替换有缺陷的基因来治疗遗传性皮肤病。儘管处于早期阶段，基因疗法有可能彻底改变皮肤病治疗方法。生物技术的进步扩大了免疫疗法在皮肤癌治疗的应用。免疫检查点抑制剂和其他免疫疗法药物已显示出治疗黑色素瘤和其他皮肤癌的功效。生物技术促进了罕见皮肤病生物学的发展，解决了以前未满足的医疗需求并增加了获得有效治疗的机会。生技公司大力投资皮肤科研究和开发，推出一系列创新产品和疗法，推动市场向前发展。这项因素将加快全球皮肤科治疗市场的需求。

可支配所得增加

随着可支配收入的增加，个人更愿意也更有能力投资优质护肤产品。这包括高端保湿霜、精华液和特殊乳霜，它们通常被认为是皮肤科护肤品的一部分。可支配收入的增加使个人能够购买药妆产品，从而弥补化妆品和药品之间的差距。此外，人们可能会选择美容皮肤科治疗，例如化学换肤、微晶磨皮和雷射治疗，这些治疗费用昂贵，但效果明显。较高的收入水平通常意味着更好地接触皮肤科医生和皮肤护理专家。必要时，人们可以寻求专业建议并接受个人化的治疗计划，包括处方皮肤病治疗。富裕人士可能会选择接受先进的皮肤科手术，如肉毒桿菌注射、真皮填充剂和雷射换肤，以解决老化问题和皮肤缺陷。

可支配收入较高的人可能更倾向于投资高品质的防晒霜和防晒服，以防止阳光伤害并降低皮肤癌的风险。收入较高的个人可以负担牛皮癣、湿疹和痤疮等慢性皮肤病的长期治疗方案，包括处方药和生物疗法。收入水准的提高通常会导致人们采用全面的护肤程序，其中包括一系列皮肤病治疗方法，包括清洁剂、保湿剂和专业治疗。购买预防性和抗衰老皮肤科产品的能力使个人能够主动解决皮肤问题，保持年轻的皮肤，并防止皮肤状况的恶化。可支配收入较高的人可能会前往以先进医疗设施和专业知识而闻名的国家寻求皮肤科治疗或美容手术。提供临床皮肤护理治疗和放鬆服务相结合的医疗水疗中心深受可支配收入人群的欢迎，推动了对各种皮肤科治疗的需求。一些富裕的消费者喜欢客製化和精品护肤解决方案，包括根据他们的特定需求量身定制的个人化护肤配方。高收入者可能会被提供独家优质皮肤科产品的豪华护肤品牌所吸引。这项因素将加速全球皮肤科治疗市场的需求。

主要市场挑战

通用竞争

当皮肤科药物的仿製药上市时，它们的售价通常比品牌药物低得多。这可能会导致品牌产品的价格下降，从而降低其市场份额和获利能力。品牌皮肤科产品通常享有一定期限的专利保护，在此期间享有市场独占权。当这些专利到期时，仿製药製造商可以用成本较低的替代品进入市场，从而减少原始品牌的市场份额。皮肤科药物仿製药的推出可能会导致开发和销售品牌产品的製药公司的销售收入急剧下降。仿製药竞争会加剧皮肤病治疗市场内的竞争，进而导致品牌和仿製药製造商面临定价压力并降低利润率。随着皮肤科药物的仿製药越来越多，市场可能会变得碎片化，多家製造商提供类似的产品。这种碎片化使得皮肤科医生和患者在各种通用选项中进行选择变得具有挑战性。包括皮肤科医生在内的医疗保健提供者可能会越来越多地开出非专利皮肤科药物以降低医疗成本。这可能会导致品牌产品的使用量下降。

市场饱和

当多家公司针对相同条件提供类似的皮肤科产品时，竞争就会变得激烈。这种竞争可能会导致价格战，从而降低所有参与者的利润率。在市场饱和的情况下，公司可能会降低价格以获得竞争优势，这可能会导致整体收入和获利能力下降。在饱和的市场中，公司越来越难以获得额外的市场份额，因为大多数潜在客户已经在使用现有产品。当众多产品治疗相同的皮肤病时，公司很难根据功效或其他因素来区分其产品。市场饱和可能会阻碍对新皮肤病疗法的研发投资，因为公司可能认为获得显着投资回报的机会有限。公司可能不会专注于开发突破性的治疗方法，而是专注于对现有产品进行渐进式改进，以维持市场份额。由于现有的客户忠诚度，成熟品牌可能在饱和市场中具有优势，这使得新进业者更难获得吸引力。

主要市场趋势

个人化医疗

遗传学和基因组学的进步使皮肤科医生能够分析患者的基因谱，以便更好地了解他们对某些皮肤状况的易感性或对特定治疗的反应。基因测试可以帮助识别与牛皮癣或黑色素瘤等疾病相关的遗传标记，从而实现个人化的治疗计划。皮肤科医生越来越多地使用生物标记（患者皮肤或血液中发现的特定分子或遗传标记物）来评估皮肤状况的严重程度并预测他们对某些疗法的反应。这有助于调整治疗方法以获得更好的结果。随着对皮肤疾病的分子机制有了更深入的了解，皮肤科医生可以开出针对性的治疗方法，包括生物製剂和小分子抑制剂，专门解决导致患者病情的途径。这种方法可以最大限度地减少副作用并最大限度地提高治疗效果。复合局部治疗可以根据个人的皮肤类型、状况和敏感性进行个人化。皮肤科医生可以与复方药剂师合作，根据患者的需求制定定製配方。个人化医疗使皮肤科医生能够识别皮肤癌或其他皮肤病风险较高的个体。这使得能够采取更主动的监测和预防措施，例如定期进行皮肤癌筛检或客製化皮肤护理程序。

细分市场洞察

药品类别见解

2022年，全球皮肤科治疗市场最大份额由抗感染药物领域占据，预计未来几年将继续扩大。皮肤感染，包括细菌、真菌和病毒感染，是世界常见的皮肤病。这些感染的范围从轻微到严重，需要治疗。因此，对抗感染皮肤病治疗有持续的需求。痤疮是一种广泛存在的皮肤病，通常由细菌感染引起或加剧。痤疮治疗，包括局部和口服抗生素，属于抗感染药物类别，并已被广泛使用。某些病毒性皮肤感染，例如单纯疱疹和带状疱疹（带状疱疹），需要抗病毒药物作为治疗的一部分。

应用洞察

2022 年，全球皮肤病治疗市场最大份额由银屑病细分市场占据，预计未来几年将继续扩大。称为牛皮癣的慢性自体免疫性皮肤病会加速皮肤细胞的发育週期。在手肘、脸部、手掌、膝盖、头皮、下背部和脚底，它会导致皮肤呈现厚红色并带有银色鳞片。斑块状干癣是最常见的一种，是由错误的 T 细胞攻击皮肤引起的。预计银屑病患病率上升、银屑病药物开发临床试验数量增加以及主要市场参与者不断进步将有助于该细分市场的成长。

区域洞察

到2022年，北美地区将主导全球皮肤病治疗市场。北美拥有发达的医疗基础设施，包括许多皮肤科诊所和专门从事皮肤疾病的医疗保健提供者。北美拥有许多领先的製药公司和研究机构，在皮肤病学研究和产品开发方面投入大量资金。该地区经常引领新疗法和疗法的开发。痤疮、牛皮癣、湿疹和皮肤癌等皮肤病在北美很普遍，增加了对皮肤病治疗的需求。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：COVID-19 对全球皮肤科治疗市场的影响

第 5 章：客户之声

第 6 章：全球皮肤科治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用（脱髮、疱疹、牛皮癣、红斑痤疮、异位性皮肤炎和其他应用）
  • 依药物类别（抗感染药、皮质类固醇、抗青春痘药、钙调神经磷酸酶抑制剂、类维生素A和其他药物类别）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 7 章：亚太地区皮肤病治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用
  • 按药物类别
  • 按国家/地区
• 亚太地区：国家分析
  • 中国皮肤病治疗协会
  • 印度皮肤科治疗
  • 澳洲皮肤科治疗中心
  • 日本皮肤科治疗协会
  • 韩国皮肤科治疗

第 8 章：欧洲皮肤科治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用
  • 按药物类别
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 9 章：北美皮肤病治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用
  • 按药物类别
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 10 章：南美洲皮肤病治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用
  • 按药物类别
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲皮肤科治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按应用
  • 按药物类别
  • 按国家/地区
• MEA：国家分析
  • 南非皮肤病治疗学
  • 沙乌地阿拉伯皮肤科治疗
  • 阿联酋皮肤科治疗

第 12 章：市场动态

• 司机
• 挑战

第 13 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 14 章：全球皮肤科治疗市场：SWOT 分析

第 15 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第 16 章：大环境分析

第17章：竞争格局

• 商业概览
• 公司概况
• 产品与服务
• 财务（上市公司）
• 最近的发展
• SWOT分析
  • Abbvie Inc. (Allergan PLC)
  • Almirall SA
  • Amgen Inc.
  • Bausch Health Companies Inc.
  • Galderma SA
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

第 18 章：策略建议

第 19 章：关于我们与免责声明

The Global Dermatological Therapeutics Market, valued at USD 18.45 billion in 2022, is poised for remarkable growth in the forecast period, projected to exhibit an impressive CAGR of 8.33% through 2028. This market is dedicated to the field of dermatological therapeutics, which encompasses the diagnosis, treatment, and management of disorders and conditions affecting the skin, hair, nails, and mucous membranes. Dermatology, as a specialized medical discipline, addresses a diverse spectrum of skin-related issues, spanning common conditions like acne and eczema to intricate disorders such as skin cancer and autoimmune diseases. The core objective of dermatological therapeutics is to provide comprehensive care, encompassing medical, surgical, and cosmetic interventions, all aimed at preserving or enhancing skin health and aesthetics.

Within the realm of dermatological therapeutics, a wide array of treatment modalities comes into play, involving pharmaceutical interventions ranging from topical creams and ointments to oral medications and biologic therapies. These therapeutic strategies are strategically employed to alleviate symptoms, mitigate inflammation, combat infections, and modulate the underlying disease processes.

Numerous compelling factors contribute to the market's growth trajectory. First and foremost, the escalating incidence of skin disorders, including but not limited to acne, psoriasis, eczema, skin cancer, and fungal infections, stands out as a significant driver. This upward trend in skin-related ailments is propelled by several factors, including population aging and the enduring impact of environmental factors on skin health. Consequently, there is a heightened demand for effective treatment options to address these conditions.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 18.45 Billion
Market Size 2028	USD 29.74 Billion
CAGR 2023-2028	8.33%
Fastest Growing Segment	Psoriasis
Largest Market	North America

Furthermore, an increasing awareness of skincare and a growing preoccupation with aesthetic concerns are reshaping the landscape. This shift in consciousness is largely driven by the pervasive influence of social media, prevailing beauty trends, and a widespread desire for a more youthful appearance. This has translated into elevated demand for dermatological products and procedures, spanning anti-aging treatments and cosmeceuticals.

In tandem with these trends, biotechnology has ushered in an era of innovation. The development of biologic therapies and personalized medicine approaches has paved the way for more targeted and efficacious treatments for various skin conditions, exemplified by advancements in managing conditions like psoriasis and atopic dermatitis.

Moreover, as disposable incomes continue to rise, particularly in emerging markets and among the global middle class, individuals are afforded greater access to dermatological treatments and an extensive array of skincare products.

In summary, the Global Dermatological Therapeutics Market stands at the forefront of skin health, poised to address the pressing need for effective diagnostics, treatments, and care regimens. The market is dynamically shaped by a confluence of factors, including the rising incidence of skin disorders, evolving beauty standards, and innovations in biotechnology, all working together to redefine and enhance the skin health and aesthetic aspirations of individuals worldwide.

Key Market Drivers

Rising Awareness and Aesthetic Concerns

Aesthetic concerns related to aging, such as fine lines, wrinkles, and age spots, drive the demand for anti-aging dermatological products and procedures. This includes the use of topical creams, injectables like Botox, and laser treatments. Many individuals seek dermal fillers to enhance facial volume and achieve a more youthful appearance. These treatments often fall under the domain of dermatological therapeutics. Chemical peels are used for skin rejuvenation, improving skin texture, and addressing aesthetic concerns like pigmentation irregularities. Aesthetic concerns about scars, whether from surgery, acne, or injuries, lead to the demand for scar management products and treatments. The desire for brighter and more even-toned skin has driven the market for dermatological products that address issues such as hyperpigmentation and melasma. Acne is a common skin condition that can lead to aesthetic concerns, especially when it results in scarring. Dermatological therapeutics, including prescription and over-the-counter products, are sought after for acne management and scar reduction.

Increasing awareness of the damaging effects of UV radiation and the importance of sun protection has led to greater use of dermatological products like sunscreens and skin cancer prevention therapies. The influence of social media, beauty influencers, and celebrity endorsements has made people more conscious of their appearance and skincare routines. This has contributed to the demand for a wide range of dermatological products. Consumers have access to more information than ever before, allowing them to educate themselves about skincare and the benefits of dermatological products. This education often leads to increased product adoption. Dermatological therapeutics have become more personalized to meet individual skincare needs. Customized skincare regimens, often recommended by dermatologists, have gained popularity. The preference for minimally invasive aesthetic procedures, such as laser therapy and microdermabrasion, has grown due to reduced downtime and natural-looking results. Celebrities openly discussing their skincare routines and endorsements of specific products or treatments can significantly influence consumer choices and boost demand. The globalization of beauty ideals, where clear and healthy skin is considered universally attractive, has led to the global demand for dermatological products and treatments. This factor will help in the development of Global Dermatological Therapeutics Market.

Advancements in Biotechnology

Biotechnology has led to the development of innovative and targeted treatments for various skin conditions. Biotechnology has enabled the creation of biologic drugs for dermatological conditions like psoriasis, atopic dermatitis, and hidradenitis suppurativa. These drugs, often monoclonal antibodies, target specific molecules in the immune system or inflammatory pathways, providing more precise and effective treatments with fewer side effects. Biotechnological advancements have facilitated personalized medicine in dermatology. Genetic testing and biomarker analysis allow dermatologists to tailor treatments to an individual's genetic makeup and disease characteristics, enhancing treatment efficacy and safety. Biotechnology has led to the development of advanced drug delivery systems, such as nanoparticles and liposomes, which enhance the penetration of therapeutic agents into the skin. This innovation improves the effectiveness of topical dermatological treatments. Biotechnology has given rise to regenerative medicine approaches in dermatology. Stem cell therapy and tissue engineering hold promise for repairing damaged skin and treating conditions like chronic wounds and scars. Biotechnological tools, including genetic sequencing and molecular diagnostics, enable more precise and early diagnosis of dermatological conditions. Timely and accurate diagnosis drives the demand for appropriate therapeutics. Biotechnology has led to the development of biocompatible and bioresorbable materials used in dermatological treatments, such as dermal fillers and sutures, for aesthetic and reconstructive purposes.

Biotechnology has improved the ability to culture skin cells and tissues in the laboratory. This facilitates research, drug testing, and the development of novel dermatological therapies. Ongoing research in gene therapy holds promise for treating genetic skin disorders by correcting or replacing faulty genes. Although in its early stages, gene therapy has the potential to revolutionize dermatological therapeutics. Advances in biotechnology have expanded the use of immunotherapy for skin cancer treatment. Immune checkpoint inhibitors and other immunotherapeutic agents have shown efficacy in treating melanoma and other skin cancers. Biotechnology has enabled the development of biology for rare dermatological conditions, addressing previously unmet medical needs and increasing access to effective treatments. Biotech companies invest heavily in dermatological research and development, leading to a pipeline of innovative products and therapies that drive the market forward. This factor will pace up the demand of Global Dermatological Therapeutics Market.

Increase in Disposable Income

With higher disposable income, individuals are more willing and able to invest in premium skincare products. This includes high-end moisturizers, serums, and specialty creams, which are often considered part of dermatological skincare. An increase in disposable income allows individuals to afford cosmeceutical products that bridge the gap between cosmetics and pharmaceuticals. Additionally, people may opt for aesthetic dermatological treatments, such as chemical peels, microdermabrasion, and laser therapy, which can be costly but provide visible results. Higher income levels often mean better access to dermatologists and skincare specialists. People can seek professional advice and receive personalized treatment plans, including prescription dermatological therapeutics, when necessary. Affluent individuals may choose to undergo advanced dermatological procedures like Botox injections, dermal fillers, and laser resurfacing to address aging concerns and skin imperfections.

People with higher disposable income may be more inclined to invest in high-quality sunscreens and sun-protective clothing to prevent sun damage and reduce the risk of skin cancer. Individuals with higher incomes can afford long-term treatment regimens for chronic skin conditions such as psoriasis, eczema, and acne, including prescription medications and biologic therapies. Rising income levels often lead to the adoption of holistic skincare routines that encompass a range of dermatological therapeutics, including cleansers, moisturizers, and specialty treatments. The ability to afford preventive and anti-aging dermatological products allows individuals to proactively address skin concerns, maintain youthful skin, and prevent the progression of skin conditions. People with higher disposable incomes may travel to seek dermatological treatments or aesthetic procedures in countries known for their advanced medical facilities and expertise. Medical spas offering a combination of clinical skincare treatments and relaxation services are popular among individuals with disposable income, driving demand for various dermatological procedures. Some affluent consumers prefer customized and boutique skincare solutions, including personalized skincare formulations tailored to their specific needs. Higher-income individuals may be drawn to luxury skincare brands that offer exclusive and premium dermatological products. This factor will accelerate the demand of Global Dermatological Therapeutics Market.

Key Market Challenges

Generic Competition

When generic versions of dermatological drugs become available, they are often sold at significantly lower prices than their branded counterparts. This can lead to price erosion for the branded products, reducing their market share and profitability. Branded dermatological products typically have patent protection for a certain period, during which they enjoy exclusivity in the market. When these patents expire, generic manufacturers can enter the market with lower-cost alternatives, reducing the market share of the original brand. The introduction of generic versions of dermatological drugs can result in a sharp decline in sales revenue for the pharmaceutical companies that developed and marketed the branded products. Generic competition can intensify competition within the dermatological therapeutics market, which can, in turn, lead to pricing pressures and reduced profit margins for both branded and generic manufacturers. As more generic versions of a dermatological drug become available, the market can become fragmented, with multiple manufacturers offering similar products. This fragmentation can make it challenging for dermatologists and patients to choose among various generic options. Healthcare providers, including dermatologists, may increasingly prescribe generic dermatological drugs to reduce healthcare costs. This can lead to a decline in the use of branded products.

Market Saturation

When multiple companies offer similar dermatological products for the same conditions, competition can become intense. This competition may lead to price wars, reducing profit margins for all players. With a saturated market, companies may lower prices to gain a competitive edge, which can result in reduced overall revenue and profitability. In a saturated market, it becomes increasingly difficult for companies to capture additional market share, as most potential customers are already using existing products. When numerous products treat the same dermatological conditions, it can be challenging for companies to differentiate their offerings based on efficacy or other factors. Market saturation can discourage investment in research and development for new dermatological therapies, as companies may perceive limited opportunities for significant returns on investment. Rather than developing groundbreaking treatments, companies may focus on making incremental improvements to existing products to maintain market share. Established brands may have an advantage in saturated markets due to existing customer loyalty, making it harder for newer entrants to gain traction.

Key Market Trends

Personalized Medicine

Advances in genetics and genomics have allowed dermatologists to analyze a patient's genetic profile to better understand their susceptibility to certain skin conditions or their response to specific treatments. Genetic testing can help identify genetic markers associated with conditions like psoriasis or melanoma, enabling personalized treatment plans. Dermatologists are increasingly using biomarkers, which are specific molecules or genetic markers found in a patient's skin or blood, to assess the severity of skin conditions and predict their response to certain therapies. This helps tailor treatment approaches for better outcomes. With a deeper understanding of the molecular mechanisms underlying skin disorders, dermatologists can prescribe targeted therapies, including biologics and small molecule inhibitors, that specifically address the pathways contributing to a patient's condition. This approach minimizes side effects and maximizes treatment efficacy. Compounded topical treatments can be personalized to suit an individual's skin type, condition, and sensitivities. Dermatologists may work with compounding pharmacists to create customized formulations tailored to the patient's needs. Personalized medicine allows dermatologists to identify individuals at higher risk of skin cancers or other dermatological conditions. This enables more proactive surveillance and preventive measures, such as regular skin cancer screenings or tailored skincare routines.

Segmental Insights

Drug Class Insights

In 2022, the Global Dermatological Therapeutics Market largest share was held by Anti-infectives segment in the forecast period and is predicted to continue expanding over the coming years. Skin infections, including bacterial, fungal, and viral infections, are common dermatological conditions worldwide. These infections can range from minor to severe and require medical treatment. As a result, there is a consistent demand for anti-infective dermatological therapeutics. Acne is a widespread skin condition often caused or exacerbated by bacterial infection. Acne treatments, including topical and oral antibiotics, fall under the anti-infectives category and have been widely prescribed. Certain viral skin infections, such as herpes simplex and shingles (herpes zoster), require antiviral medications as part of their treatment.

Application Insights

In 2022, the Global Dermatological Therapeutics Market largest share was held by Psoriasis segment and is predicted to continue expanding over the coming years. Chronic autoimmune skin disease called psoriasis quickens the development cycle of skin cells. On the elbows, face, palms, knees, scalp, lower back, and soles of feet, it results in regions of thickly red skin with silvery scales. Plaque psoriasis, the most prevalent kind, is brought on by mistaken T-cell attacks on the skin. The segment's growth is anticipated to be aided by the rising prevalence of psoriasis, the rising number of clinical trials for psoriasis drug development, and the rising advances by key market participants.

Regional Insights

The North America region dominates the Global Dermatological Therapeutics Market in 2022. North America boasts a well-developed healthcare infrastructure, including many dermatology clinics and healthcare providers specializing in skin disorders. North America is home to many leading pharmaceutical companies and research institutions that invest heavily in dermatological research and product development. This region often leads in the development of new therapies and treatments. Skin conditions like acne, psoriasis, eczema, and skin cancer are prevalent in North America, contributing to the demand for dermatological therapeutics.

Key Market Players

• Abbvie Inc. (Allergan PLC)

• Almirall SA

• Amgen Inc.

• Bausch Health Companies Inc.

• Galderma SA

• GlaxoSmithKline PLC

• Johnson & Johnson

• Novartis AG

• Pfizer Inc.

• Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Dermatological Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dermatological Therapeutics Market, By Application:

• Alopecia
• Herpes
• Psoriasis
• Rosacea
• Atopic Dermatitis
• Other Applications

Dermatological Therapeutics Market, By Drug Class:

• Anti-infectives
• Corticosteroids
• Anti-acne
• Calcineurin Inhibitors
• Retinoids
• Other Drug Classes

Dermatological Therapeutics Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Dermatological Therapeutics Market.

Available Customizations:

• Global Dermatological Therapeutics Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Dermatological Therapeutics Market

5. Voice of Customer

6. Global Dermatological Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Other Applications)
  • 6.2.2. By Drug Class (Anti-infectives, Corticosteroids, Anti-acne, Calcineurin Inhibitors, Retinoids, and Other Drug Classes)
  • 6.2.3. By Region
  • 6.2.4. By Company (2022)
• 6.3. Market Map

7. Asia Pacific Dermatological Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Drug Class
  • 7.2.3. By Country
• 7.3. Asia Pacific: Country Analysis
  • 7.3.1. China Dermatological Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Drug Class
  • 7.3.2. India Dermatological Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Drug Class
  • 7.3.3. Australia Dermatological Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Drug Class
  • 7.3.4. Japan Dermatological Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Drug Class
  • 7.3.5. South Korea Dermatological Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Drug Class

8. Europe Dermatological Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Drug Class
  • 8.2.3. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Dermatological Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Drug Class
  • 8.3.2. Germany Dermatological Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Drug Class
  • 8.3.3. Spain Dermatological Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Drug Class
  • 8.3.4. Italy Dermatological Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Drug Class
  • 8.3.5. United Kingdom Dermatological Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Drug Class

9. North America Dermatological Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Drug Class
  • 9.2.3. By Country
• 9.3. North America: Country Analysis
  • 9.3.1. United States Dermatological Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Drug Class
  • 9.3.2. Mexico Dermatological Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Drug Class
  • 9.3.3. Canada Dermatological Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Drug Class

10. South America Dermatological Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Drug Class
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dermatological Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Drug Class
  • 10.3.2. Argentina Dermatological Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Drug Class
  • 10.3.3. Colombia Dermatological Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Drug Class

11. Middle East and Africa Dermatological Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Application
  • 11.2.2. By Drug Class
  • 11.2.3. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Dermatological Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Application
      • 11.3.1.2.2. By Drug Class
  • 11.3.2. Saudi Arabia Dermatological Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Application
      • 11.3.2.2.2. By Drug Class
  • 11.3.3. UAE Dermatological Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Application
      • 11.3.3.2.2. By Drug Class

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Dermatological Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

• 17.1. Business Overview
• 17.2. Company Snapshot
• 17.3. Products & Services
• 17.4. Financials (In case of listed companies)
• 17.5. Recent Developments
• 17.6. SWOT Analysis
  • 17.6.1. Abbvie Inc. (Allergan PLC)
  • 17.6.2. Almirall SA
  • 17.6.3. Amgen Inc.
  • 17.6.4. Bausch Health Companies Inc.
  • 17.6.5. Galderma SA
  • 17.6.6. GlaxoSmithKline PLC
  • 17.6.7. Johnson & Johnson
  • 17.6.8. Novartis AG
  • 17.6.9. Pfizer Inc.
  • 17.6.10. Bristol-Myers Squibb Company

18. Strategic Recommendations

19. About Us & Disclaimer